<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973125</url>
  </required_header>
  <id_info>
    <org_study_id>2018KYPJ082</org_study_id>
    <nct_id>NCT03973125</nct_id>
  </id_info>
  <brief_title>Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma</brief_title>
  <acronym>IVCCCH</acronym>
  <official_title>Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma: Short-term Follow-up of Anatomical and Functional Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the safety and effectiveness of application of
      intravitreal conbercept injection as the primary treatment for exudative circumscribed
      choroidal haemangioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective clinical trial aims to evaluate the safety and effectiveness study of
      intravitreal conbercept injection as the primary treatment for exudative circumscribed
      choroidal haemangioma: (1)To evaluate therapeutic effect (including both anatomical and
      functional responses to intravitreal conbercept injection) of intravitreal conbercept
      injectionfor exudative circumscribed choroidal haemangioma; (2)To evaluate the safety
      (including side effects of the eye as well as side effects of system) of intravitreal
      conbercept injection for exudative circumscribed choroidal haemangioma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2014</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>half a year</time_frame>
    <description>change of best corrected visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central foveal thickness</measure>
    <time_frame>half a year</time_frame>
    <description>change of central foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Circumscribed Choroidal Haemangioma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conbercept</intervention_name>
    <description>After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) patients with circumscribed choroidal haemangioma who was diagnosed using
             ophthalmoscopy, fluorescein/indocyanine green angiography, and ultrasonography; 2)
             presence of reduced visual acuity or metamorphopsia; and 3) subretinal fluid involving
             the fovea.

        Exclusion Criteria:

          -  patients with abnormal liver function test results, liver disease, porphyria, or
             previous treatment for circumscribed choroidal haemangioma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chenjin Jin, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kunbei Lai</last_name>
    <phone>8602087331366</phone>
    <email>laikb@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenjin Jin, Ph.D.</last_name>
    <phone>Study Principal Investigator</phone>
    <email>jinchj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kunbei Lai</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunbei Lai</last_name>
      <phone>18825135810</phone>
      <email>laikb@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chenjin Jin</last_name>
      <phone>13302209900</phone>
    </contact_backup>
    <investigator>
      <last_name>Chenjin Jin, ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 2, 2019</last_update_submitted>
  <last_update_submitted_qc>June 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Chen-jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>circumscribed choroidal haemangioma</keyword>
  <keyword>conbercept</keyword>
  <keyword>effectiveness</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

